Gilead’s $4.3B Bet on CymaBay Pays Off With FDA Nod for Autoimmune Liver Disease Drug

The regulator’s approval of Livdelzi for primary biliary cholangitis under the accelerated pathway is a boost to Gilead Sciences’ liver disease business. Analysts expect the drug to reach more than $1 billion in sales.

Read more about this post on Biospace